retatrutide phase 3 triumph just had its biggest data year yet. In 2026, Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist posted two major readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight 🚨 HOT OFF THE PRESS:

Patients commonly contact us from: Telehealth consultations make it possible for eligible patients throughout Florida to discuss medical weight loss treatment options from the comfort of home

GLP-1s work by slowing stomach emptying, increasing feelings of fullness, and reducing appetite

Im not as bloated

Managing side effects at the starting dose Even at the lowest starting doses, some people experience side effects

They mimic a hormone that the body is supposed to produce naturally, which increases the amount of insulin released by the pancreas in order to control blood sugar

Many times, we have to jump through a lot of hoops, Low Wang said